Abstract
The relationship between CYP450 and P-gp occurs at different levels. It is known that certain substrates of P-gp undergo metabolic transformations by various CYP450 isoforms; in addition some of them demonstrated to be activators of both P-gp and CYP450. The majority of such compounds are well-known chemotherapeutics, therefore the purpose of this review is to clarify whether there is a relationship between the simultaneous modulation of CYP450 and P-gp and the onset of drug resistance in tumors treatment. Here, we discuss the biological aspects of the topic in relation to the various tissues distribution of CYP450 and P-gp, the recent findings regarding the ability of some chemotherapeutics in modulating both P-gp and CYP450, whether this modulation is ultimately responsible for the onset of drug resistance in cancer treatment and the promising role of gene polymorphisms in determining the interindividual variability in drug responses in clinical practice.
Keywords: Cancer, CYP450, Glycoprotein P, platinum compounds, resistance to chemotherapy, tyrosine kinase inhibitors, chemotherapeutics, Dubin-Johnson syndrome, ATP-Binding Cassette (ABC) proteins, Byler's disease
Current Drug Metabolism
Title: The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Volume: 12 Issue: 8
Author(s): Amalia Azzariti, Letizia Porcelli, Anna Elisa Quatrale, Nicola Silvestris and Angelo Paradiso
Affiliation:
Keywords: Cancer, CYP450, Glycoprotein P, platinum compounds, resistance to chemotherapy, tyrosine kinase inhibitors, chemotherapeutics, Dubin-Johnson syndrome, ATP-Binding Cassette (ABC) proteins, Byler's disease
Abstract: The relationship between CYP450 and P-gp occurs at different levels. It is known that certain substrates of P-gp undergo metabolic transformations by various CYP450 isoforms; in addition some of them demonstrated to be activators of both P-gp and CYP450. The majority of such compounds are well-known chemotherapeutics, therefore the purpose of this review is to clarify whether there is a relationship between the simultaneous modulation of CYP450 and P-gp and the onset of drug resistance in tumors treatment. Here, we discuss the biological aspects of the topic in relation to the various tissues distribution of CYP450 and P-gp, the recent findings regarding the ability of some chemotherapeutics in modulating both P-gp and CYP450, whether this modulation is ultimately responsible for the onset of drug resistance in cancer treatment and the promising role of gene polymorphisms in determining the interindividual variability in drug responses in clinical practice.
Export Options
About this article
Cite this article as:
Azzariti Amalia, Porcelli Letizia, Elisa Quatrale Anna, Silvestris Nicola and Paradiso Angelo, The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy, Current Drug Metabolism 2011; 12 (8) . https://dx.doi.org/10.2174/138920011798357042
DOI https://dx.doi.org/10.2174/138920011798357042 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents
Current Medicinal Chemistry New Trends in Fiber-Optic Chemical and Biological Sensors
Current Analytical Chemistry The Beneficial Effects of QIAPI 1<sup>®</sup> against Pentavalent Arsenic-Induced Lung Toxicity: A Hypothetical Model for SARS CoV2-I nduced Lung Toxicity
Current Pharmaceutical Biotechnology Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Physical and Chemical Stimuli-Responsive Drug Delivery Systems: Targeted Delivery and Main Routes of Administration
Current Pharmaceutical Design Mouse Strains for Prostate Tumorigenesis Based on Genes Altered in Human Prostate Cancer
Current Drug Targets Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry General Aspects of Metal Toxicity
Current Medicinal Chemistry Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review
Current Cancer Drug Targets Herbal Phytochemicals as Immunomodulators
Current Immunology Reviews (Discontinued) Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
Current Drug Targets Cholecystokinin Antagonists A New Way to Improve the Analgesia from Old Analgesics?
Current Pharmaceutical Design Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Current Pharmaceutical Biotechnology Regulation of MicroRNAs by Phytochemicals: A Promising Strategy for Cancer Chemoprevention
Current Cancer Drug Targets